Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmi

Guideline Title
Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States.

Bibliographic Source(s)
Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Rockville (MD): Public Health Service Task Force; 2010 May 24. Various p. [574 references]

Guideline Status
This is the current release of the guideline.

This guideline updates a previous version: Perinatal HIV Guidelines Working Group. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Rockville (MD): Public Health Service Task Force; 2009 Apr 29. 111 p. [388 references]


FDA Warning/Regulatory Alert
Note from the National Guideline Clearinghouse: This guideline references drugs for which important revised regulatory information has been released.

February 16, 2010 – Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp : The U.S. Food and Drug Administration (FDA) and Amgen notified healthcare professionals and patients that all erythropoiesis-stimulating agents (ESAs) must be used under a risk evaluation and mitigation strategy (REMS) risk management program. As part of the risk management program, a Medication Guide explaining the risks and benefits of ESAs must be provided to all patients receiving an ESA.

January 29, 2010 – Videx (didanosine) : The U.S. Food and Drug Administration (FDA) notified healthcare professionals and patients about a rare, but serious, complication in the liver known as non-cirrhotic portal hypertension in patients using Videx or Videx EC (didanosine), a medication used to treat human immunodeficiency virus (HIV) infection. Because of the potential severity of portal hypertension, including death from hemorrhaging esophageal varices, FDA has revised the Warning and Precautions section of the didanosine drug label to assure safe use of the medication.

December 3, 2009 – Lexiva (fosamprenavir) : GlaxoSmithKline and the U.S. Food and Drug Administration (FDA) notified healthcare professionals of modifications to the existing Warnings and Precautions section of the Prescribing Information including notification that increases in cholesterol have occurred with treatment, new emphasis on lipids management, and a recommendation that triglyceride and cholesterol testing be performed prior to initiating therapy with LEXIVA and at periodic intervals during therapy.

open here to see the full-text (large):
http://guideline.gov/content.aspx?f=rss&id=16305